AVN-397 is a5-hydroxytryptamine subtype 6 receptorantagonist drug developed by Avineuro Pharmaceuticals Inc. that can potentially be used to treatAlzheimer's disease andgeneral anxiety disorder (GAD).[1][2] Avineuro announced that it would startPhase II clinical trials in 2009, and those trials were ongoing as of 2012.[3][4][5]Phase II trials are now listed as Discontinued.[6][7]
 | This article about ananxiolytic is astub. You can help Wikipedia byexpanding it. |